97175 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Platelet compositions and methods for the delivery of therapeutic agents
#2402COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERS
#2403Intravesical therapy for bladder cancer
#2404Anti-B7-H4 antibodies and immunoconjugates
#2405IMMUNE-STIMULATING PEPTIDES AND CHECKPOINT INHIBITORS, AND USES THEREOF FOR TREATING CANCER
#2406BISPECIFIC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#2407Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
#2408Single-domain antibodies and variants thereof against CTLA-4
#2409Fabs-in-tandem immunoglobulin and uses thereof
#2410Combination therapy with glutaminase inhibitors and immuno-oncology agents
#2411SPHERICAL NUCLEIC ACID TLR9 AGONISTS
#2412Anti-PD-L1 antibodies and variants
#2413Anti-LAG-3 antibodies and uses thereof
#2414Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
#2415COMPOSITIONS AND METHODS OF TREATING CANCER
#2416Therapeutic and diagnostic methods for cancer
#2417Chimeric poxvirus compositions and uses thereof
#2418Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
#2419Anti-PD-L1 antibodies and methods of use
#2420CTLA4 fusion proteins for the treatment of diabetes
#2421Diagnostic anti-PD-L1 antibody and use thereof
#2422Pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
#2423Amino acid sequences that modulate the interaction between cells of the immune system
#2424COMBINATION THERAPY WITH A MEK INHIBITOR, A PD-1 AXIS INHIBITOR, AND A TAXANE
#2425PEPTIDE VACCINES AND DURVALUMAB FOR TREATING BREAST CANCER
#2426Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
#2427MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
#2428Carrier-PD-L1 binding agent compositions for treating cancers
#2429Method of altering an antibody-related adverse event based on SCD163 and/or CXCL5 levels
#2430Combining adenovirus and checkpoint inhibitors for treating cancer
#2431ENHANCEMENT OF THE IMMUNE RESPONSE
#2432Anti-CD277 antibodies
#2433Adenovirus and immunomodulator combination therapy
#2434Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
#2435Immunomodulating treatments of body cavities
#2436BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#2437KLRG1 DEPLETION THERAPY
#2438Methods of sensitizing cancer to immunotherapy
#2439Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
#2440Single domain binding molecule
#2441METHODS OF TREATMENT WITH ANTAGONISTS AGAINST PD-1 AND PD-L1 IN COMBINATION WITH RADIATION THERAPY
#2442Improved Therapeutic Index of Anti-Immune Checkpoint Inhibitors Using Combination Therapy Comprising A PHY906 Extract, A Scutellaria baicalensis Georgi (S) Extract or A Compound From Such Extracts
#2443COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE
#2444Combination therapy with Notch and PD-1 or PD-L1 inhibitors
#2445Therapeutic heterocyclic compounds
#2446Binding molecules with modified J-chain
#2447Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#2448TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL MICROFLORA
#2449Combination taxoid nanoemulsion with immunotherapy in cancer
#2450Anti-PD-L1 nanobody, coding sequence and use thereof
#2451Anti-C10ORF54 antibodies and uses thereof
#2452IMMUNOSWITCH NANOPARTICLES FOR REPROGRAMMED T CELL RESPONSES
#2453PROTAC antibody conjugates and methods of use
#2454Pharmaceutical composition for preventing or treating cancer and method using thereof
#2455Targeting PD-L1 on tumor cells
#2456COMBINATION THERAPY WITH A MEK INHIBITOR, A PD-1 AXIS INHIBITOR, AND A VEGF INHIBITOR
#2457Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
#2458METHODS FOR REGULATING ENDOGENOUS PRODUCTION OF CHECKPOINT MOLECULE ANTAGONISTS
#2459TREATMENT OF CANCER USING A COMBINATION OF IMMUNOMODULATION AND CHECK POINT INHIBITORS
#2460Immune adjuvant for cancer
#2461Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
#2462MRNA display antibody library and methods
#2463Methods of treating colorectal cancer
#2464Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2465Therapeutic antitumor combination of a TLR4 ligand with other treatments
#2466COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS
#2467Methods of using anti-lap antibodies
#2468PD-1/PD-L1 Inhibitors for Cancer Treatment
#2469PD-L1 Antibodies
#2470Anti-PD-1 antibodies and uses thereof
#2471Anti-PD-1 antibodies and compositions
#2472Oncolytic viruses targeting STAT3
#2473Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
#2474ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION
#2475COMPOSITIONS AND TREATMENT METHODS FOR CANCER IMMUNOTHERAPY
#2476CD80 variant immunomodulatory proteins and uses thereof
#2477Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2478Methods of using PD-L1 expression in treatment decisions for cancer therapy
#2479Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
#2480Anti-SIRPa antibodies and their therapeutic applications
#2481GALECTIN IMMUNOTHERAPY
#2482Anti-Galectin-9 antibodies and uses thereof
#2483B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
#2484High affinity B7-H6 antibodies and antibody fragments
#2485THERAPEUTIC AGENT FOR SOLID CANCER
#2486Anti-neuropilin antigen-binding proteins and methods of use thereof
#2487ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#2488Anti-CD3 antibodies and methods of use
#2489Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2490Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2491Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#2492Highly sensitive and specific luciferase based reporter assay for antigen detection
#2493PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
#2494Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
#2495Anti-TIGIT antibodies
#2496Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2497Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2498Methods for reducing toxicity of a chemotherapeutic drug
#2499DRUG FOR CANCER THERAPY CHARACTERIZED IN THAT AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR ARE ADMINISTERED IN COMBINATION
#2500Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
#2501Tumor mutational load
#2502Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2503Antigen binding proteins that bind PD-L1
#2504Phage-displayed single-chain variable fragment libraries and uses thereof
#2505STROMAL GENE SIGNATURES FOR DIAGNOSIS AND USE IN IMMUNOTHERAPY
#2506B7-H4 antibodies and methods of use thereof
#2507Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
#2508Anti-human PD-L1 humanized monoclonal antibody and application thereof
#2509TIGIT-binding agents and uses thereof
#2510Constrained conditionally activated binding proteins
#2511Methods of treating cancer
#2512Method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8
#2513CD8 binding agents
#2514Combination cancer therapy
#2515Anti-B7-H4 antibodies and immunoconjugates
#2516Antigen binding proteins that bind PD-L1
#2517BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
#2518Binding members to PD-L1
#2519Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#2520MODIFIED CELLS FOR IMMUNOTHERAPY
#2521ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
#2522Regulatory T cell mediator proteins and uses thereof
#2523Oncolytic viral delivery of therapeutic polypeptides
#2524Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#2525CD3-binding molecules capable of binding to human and non-human CD3
#2526METHODS FOR MONITORING AND TREATING CANCER
#2527Anti-C10orf54 antibodies and uses thereof
#2528Anti-C10orf54 antibodies and uses thereof
#2529COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS
#2530Therapeutic and diagnostic methods for cancer
#2531Anti-PD-L1 nanobody and use thereof
#2532Checkpoint blockade and microsatellite instability
#2533IL-15-based molecules and methods of use thereof
#2534BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
#2535Anti-CD3 antibodies and methods of use
#2536Activatable anti-PDL1 antibodies, and methods of use thereof
#2537ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#2538Antibodies binding LAG-3 and uses thereof
#2539Combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor
#2540Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
#2541HHLA2 as a novel inhibitor of human immune system and uses thereof
#2542Anti-PD-L1 antibodies and uses thereof
#2543Checkpoint inhibitor bispecific antibodies
#2544Antibody-drug conjugate
#2545Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
#2546METHODS AND REAGENTS TO TREAT AUTOIMMUNE DISEASES AND ALLERGY
#2547Administration of kynurenine depleting enzymes for tumor therapy
#2548Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof
#2549Methods of identifying immune cells in PD-L1 positive tumor tissue
#2550Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#2551Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
#2552Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
#2553Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
#2554METHODS FOR TREATMENT AND SELECTION OF PATIENTS RESPONSIVE TO IMMUNE MEDIATED CANCER THERAPY
#2555STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF
#2556Combination of DR5 agonist and anti-PD-1 antagonist and methods of use
#2557Human monoclonal anti-PD-L1 antibodies and methods of use
#2558COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
#2559Anti-PD-L1 antibodies and uses thereof
#2560Anti-PD-L1 antibodies and uses thereof
#2561Anti-PD-L1 combinations for treating tumors
#2562PD-L1-BINDING AGENTS AND USES THEREOF
#2563PD-1 and CTLA-4 dual inhibitor peptides
#2564PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
#2565Targeted and mutated human-interferon fusion proteins
#2566Single domain antibody and derivative proteins thereof against programmed death-ligand (PDL1)
#2567Method for identifying antigen-specific T cell receptors in primate
#2568Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2569METHODS FOR TREATING CANCER
#2570Immunoresponsive methods of treating tumors
#2571BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#2572Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2573Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
#2574Immunomagnetic nanocapsule and kit for treating cancer
#2575Anti-VISTA antibodies and fragments
#2576PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
#2577Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
#2578COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS
#2579Antibodies against TIM3 and uses thereof
#2580Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
#2581COMBINATION THERAPY FOR CANCER
#2582HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR
#2583SINGLE DOMAIN ANTIBODY AND DERIVATIVE PROTEINS THEREOF AGAINST PROGRAMMED DEATH-LIGAND (PDL1)
#2584Anti-PD-L1-anti-TIM-3 bispecific antibodies
#2585Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
#2586TUMOR BURDEN AS MEASURED BY CELL FREE DNA
#2587Methods to protect transplanted tissue from rejection
#2588Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
#2589Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2590Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2591Anti-TIGIT anibodies, anti-PVRIG antibodies and combinations thereof
#2592METHODS AND COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS ANTAGONISTS AND HPK1 ANTAGONISTS
#2593Newcastle disease viruses and uses thereof
#2594Treating and preventing microbial infections
#2595Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2596Combination therapy for treatment of disease
#2597METHODS FOR TREATING AND/OR PREVENTING A TUMOR GROWTH, INVASION AND/OR METASTASIS
#2598Immune checkpoint inhibitor combinations
#2599Chemoimmunotherapy for epithelial cancer
#2600Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
#2601B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
#2602Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof
#2603METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS
#2604Selection of patients for combination therapy
#2605Recombinant vectors comprising 2A peptide
#2606Combination comprising immunostimulatory oligonucleotides
#2607METHODS OF TREATING HER2-POSITIVE CANCER
#2608COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#2609Combination immunotherapy for the treatment of cancer
#2610COMBINATION OF THERAPEUTIC VACCINE AND PD-1-RELATED BLOCKADE FOR TREATING HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASES
#2611COMPOSITIONS AND METHODS FOR TREATING SOLID TUMORS
#2612PD-1/PD-L1 inhibitors for the treatment of cancer
#2613Immune checkpoint molecular fitness profiling by mass spectrometry
#2614PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
#2615VISTA Agonist and Methods of Use
#2616METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS
#2617Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
#2618LYMPHOTOXIN-BETA RECEPTOR-BINDING AGENTS, TARGETING ANTIBODIES, AND USES THEREOF
#2619Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
#2620TREATMENT OF CANCER WITH THERAPEUTIC MONOCLONAL ANTIBODY SPECIFIC FOR A TUMOR ASSOCIATED ANTIGEN AND AN IMMUNE ADJUVANT
#2621PD-L1 promoter methylation in cancer
#2622Vista modulators for diagnosis and treatment of cancer
#2623Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
#2624Anti-PD-L1 antibodies and uses thereof
#2625B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE
#2626Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
#2627COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1
#2628PD-L1 antibodies and uses thereof
#2629Bispecific binding proteins that bind CD40 and mesothelin
#2630Anti-CD276 antibodies (B7H3)
#2631Anti-neuropilin antigen-binding proteins and methods of use thereof
#2632Human antibodies to PD-L1
#2633Antibody molecules to PD-L1 and methods of treating cancer
#2634Anti-TIGIT antibodies and methods of use
#2635Human antibodies to PD-1
#2636Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors
#2637ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES
#2638Checkpoint inhibitor and a whole cell for use in cancer therapy
#2639TREATMENT OF CANCER BY COMBINED BLOCKADE OF THE PD-1 AND CXCR4 SIGNALING PATHWAYS
#2640COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#2641Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
#2642Therapeutic compositions, combinations, and methods of use
#2643METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND AN ANTI-CD20 ANTIBODY
#2644Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
#2645PD-L1 antagonist combination treatments
#2646COMBINATION CANCER THERAPIES
#2647Anti-PD-L1 antibodies
#2648PD-L1 binding fibronectin type III domains
#2649Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
#2650COMBINATION THERAPY OF ANTIBODY BINDING TO ANGIOPOIETIN 2 WITH ANTIBODY BINDING TO PROGRAMMED DEATH LIGAND 1
#2651COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS
#2652TREATMENT OF PD-L1 POSITIVE LUNG CANCER USING AN ANTI-PD-1 ANTIBODY
#2653BTLA Antibodies and Uses Thereof
#2654Substituted pyrimidines containing acidic groups as TLR7 modulators
#2655COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS
#2656COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY
#2657COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION
#2658Compositions, articles of manufacture and methods for treating cancer
#2659Immunomodulatory and oncolytic minicells and methods of use
#2660Compositions and methods for treating cancer
#2661Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
#2662Antibodies reactive with B7-H3 and users thereof
#2663Nano-Devices for Detection and Treatment of Cancer
#2664Synergistic nanotherapy systems and methods of use thereof
#2665COMBINATION THERAPY FOR CANCER
#2666CAR T-CELLS FOR THE TREATMENT OF B7-H4 EXPRESSING SOLID TUMORS
#2667Antibodies specific to glycosylated PD-L1 and methods of use thereof
#2668Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
#2669SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION
#2670Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index
#2671Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#2672Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
#2673Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
#2674Antibodies against signal-regulatory protein alpha and methods of use
#2675TGFbeta Receptor II Antibodies
#2676Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
#2677COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#2678Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer
#2679COMBINED ANTI-PLD-1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL LUNG CANCER
#2680ANTI-H7CR ANTIBODIES
#2681Anti-human vista antibodies and use thereof
#2682Combination immunotherapy for treating cancer
#2683COMPOSITIONS AND METHODS OF TREATING RENAL CELL CANCER
#2684Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
#2685NON-INVASIVE IMAGING OF TUMOR PD-L1 EXPRESSION
#2686Antibody-drug conjugate produced by binding through linker having hydrophilic structure
#2687Anti-B7-H6 antibody, fusion proteins, and methods of using the same
#2688Anti-ICOS antibodies
#2689ANTI-H7CR ANTIBODIES
#2690Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#2691ANTI-PD-L1 IMMUNOTOXIN FOR USE IN THERAPY
#2692Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
#2693Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancer
#2694Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
#2695COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
#2696COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT
#2697CD27 AGONISTS
#2698Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
#2699Beta-catenin inhibitors in cancer immunotherapy
#2700THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER